Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A new -class milbemycin, 13hydroxy milbemycin (), was isolated from the fermentation broth of a mutant of genetically engineered strain AVE-H39. Its structure and absolute configuration were elucidated by extensive spectroscopic methods and confirmed by single crystal X-ray diffraction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14786419.2021.1986496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of impact resistant immediate release amorphous solid dispersion via hot-melt extrusion and injection molding.
Int J Pharm
July 2025
Department of Chemistry, Franklin College of Arts and Sciences, University of Georgia, 140 Cedar St., Athens, GA 30602, USA; School of Chemical, Materials, and Biomedical Engineering, College of Engineering, University of Georgia, 597 D.W. Brooks Dr., Athens, GA 30602, USA; New Materials Institute,
Immediate release (IR) amorphous solid dispersion (ASD) tablets are currently manufactured via a multi-step process which includes hot melt extrusion (HME), grinding of the extrudate, sieving to achieve narrow particle size, blending with other excipients, and finally, direct compression. Due to the multi-step nature of the process, the production time and costs are much higher for ASD tablets than conventional tablets. Thus, a new and more efficient method of IR-ASD tablet production using HME coupled with injection molding (IM) was explored as a viable alternative.
View Article and Find Full Text PDFUnveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care.
Pharmaceutics
May 2025
Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Long-acting injectable (LAI) formulations have revolutionized veterinary pharmaceuticals by improving patient compliance, minimizing dosage frequency, and improving therapeutic efficacy. These formulations utilize advanced drug delivery technologies, including microspheres, liposomes, oil solutions/suspensions, in situ-forming gels, and implants to achieve extended drug release. Biodegradable polymers such as poly(lactic--glycolic acid) (PLGA), and polycaprolactone (PCL) have been approved by the USFDA and are widely employed in the development of various LAIs, offering controlled drug release and minimizing the side effects.
View Article and Find Full Text PDFEfficacy of an oral combination of afoxolaner and milbemycin oxime for the prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs.
Parasit Vectors
April 2025
Boehringer Ingelheim Animal Health, Lyon, France.
Background: Canine babesiosis is a tick-borne disease of significant veterinary importance in dogs. It is caused by Babesia canis in Europe, where it is transmitted by Dermacentor reticulatus ticks.
Methods: A blinded, randomized, good clinical practice (GCP) and negative control experimental study was conducted to verify the efficacy of NexGard Spectra® in reducing the transmission of B.
The Ivermectin Related Compound Moxidectin Can Target Apicomplexan Importin α and Limit Growth of Malarial Parasites.
Cells
January 2025
Nuclear Signaling Laboratory, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
Signal-dependent transport into and out of the nucleus mediated by members of the importin (IMP) superfamily is crucial for eukaryotic function, with inhibitors targeting IMPα being of key interest as anti-infectious agents, including against the apicomplexan species and , causative agents of malaria and toxoplasmosis, respectively. We recently showed that the FDA-approved macrocyclic lactone ivermectin, as well as several other different small molecule inhibitors, can specifically bind to and inhibit and IMPα functions, as well as limit parasite growth. Here we focus on the FDA-approved antiparasitic moxidectin, a structural analogue of ivermectin, for its IMPα-targeting and anti-apicomplexan properties for the first time.
View Article and Find Full Text PDFQuantitative DNA metabarcoding reveals species composition of a macrocyclic lactone and pyrantel resistant cyathostomin population in the UK.
Int J Parasitol Drugs Drug Resist
April 2025
Bristol Veterinary School, University of Bristol, Bristol, BS40 5DU, UK.
Cyathostomins are the most abundant equid endoparasites globally. There are approximately fifty cyathostomin species and, whilst they occupy distinct niches within the large intestine, they are generally considered to share similar characteristics in terms of pathogenicity and response to drug treatment. There are three classes of anthelmintic licensed in the UK to treat cyathostomins (benzimidazoles, tetrahydropyrimidines and macrocyclic lactones) and cases of resistance have been documented for all classes.
View Article and Find Full Text PDF